Infectious Diseases

Immune surveillance study shows pandemic interventions suppressed viral exposure in children, driving post-COVID resurgence and future outbreak risk.

Low-dose methylprednisolone is as effective as high-dose for severe pediatric MPP and has fewer side effects, supporting safer treatment strategies.

Biennial HPV testing and higher vaccination rates could help South Korea eliminate cervical cancer up to a decade earlier than current policy.

The baby had mild respiratory distress after delivery and briefly required supplemental blow-by oxygen during transitioning.

The AAP recommends that all children aged 6 months to 23 months receive a COVID-19 vaccine, as this group has the highest risk for severe infection.

What's the diagnosis?

Among adolescents aged 13 to 17, coverage with 1 or more Tdap doses increased from 89% to 91.3% from 2023 to 2024.

The authors of a recent study on flu-linked necrotizing encephalopathy in children present a deep dive into their findings and the biggest takeaways from the study.

As families prepare for a new school year, pediatricians are essential in helping parents navigate immunization schedules and school requirements and ensuring vaccine confidence.

New CDC data show fewer kindergartners are fully vaccinated as exemption rates increased during the 2024-2025 school year.

Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head back to school.

“While our study is small, its results are powerful and have implications not only for MIS-C, but potentially for long COVID,” said lead author Lael Yonker, MD.

Of the 253 influenza-related pediatric deaths through June 21, 2025, 42.7% occurred in children without a high-risk medical condition.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

This week, HHS Secretary Robert F. Kennedy Jr signed the ACIP's recommendation to remove the mercury-based preservative from all influenza vaccines.

Nirsevimab reduced RSV-related illness by up to 98% and lowered the amount of hospitalizations and health care use among healthy term infants in a real-world study.

Early antibiotic exposure disrupts infant immune development by altering gut microbiota, highlighting inosine's potential as a therapeutic target for immune restoration.

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

A week into July 2025, the total reported cases in the United States have surpassed the peak of 1274 cases recorded for all 2019.

Six medical societies, including the American Academy of Pediatrics, are suing the HHS and its Secretary to "defend vaccine policy."

Mycoplasma pneumoniae caused 1 in 2 pediatric pneumonia hospitalizations in 2024, with sharp increases seen across all age groups, according to a recent CDC MMWR report.

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

The American Academy of Pediatrics will continue to hold its own childhood vaccine schedule, as it has since the 1930s.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on how PNPs can implement evidence-based strategies to encourage parents to vaccinate their children.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

Ramilo, a clesrovimab clinical trial investigator, breaks down the recent FDA approval for the newest monoclonal antibody to protect against RSV disease in infants.

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

Aaron Milstone, MD, emphasizes the need for better recognition and prevention of Staphylococcus aureus infections in neonatal intensive care units.

Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.